Kiadis Pharma in brief
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.
With regard to Kiadis Pharma’s lead product ATIR™, and based upon a phase I/II dose escalation study providing early proof of concept of the safety and efficacy of ATIRTM, Kiadis Pharma started a larger phase II/III study in 2009 which was terminated early in 2012 due to major manufacturing issues. At the same time, Hospira, Inc., Kiadis Pharma’s partner for ATIR™ in Europe, terminated its agreement with Kiadis Pharma. The manufacturing issues encountered by Kiadis Pharma have been resolved and it is anticipated that a multi-center phase II exploratory study to evaluate the safety and efficacy of ATIRTM will commence enrolling patients early 2013.